| 美国 | |||
| 证券 交易委员会 | |||
| 华盛顿， 特区 20549 | |||
| 日程安排 13G | |||
| (Rule 13d-102) | |||
| 资讯 声明根据规则13d-1和13d-2 | |||
| 根据1934年证券交易法案 | |||
| （修正案 编号1）* | |||
| 亮智生物科技公司 | |||
| (发行人 名称) | |||
| 普通股份，无面值 | |||
| （证券分类名称）的标题 | |||
| 10919W405 | |||
| (CUSIP 号码) | |||
| 2024年10月15日 | |||
| (需要提交声明的事件日期) | |||
请勾选适用的规则，根据该规则提交此附表:
| ¨ | 第13d-1(b)条规定 |
| x | 第13d-1(c)条规定 |
| ¨ | 规则13d-1(d) |
* 本封面的其余部分 将填写在报告人对于有关证券类别的初始提交此表格时，以及任何 后续修订包含可能改变前封面提供的披露资讯的情况。
本封面所要求提供的信息，不应被视为《证券交易法》第18条的“申报文档”，也不应承担该法律条款下的任何责任，但须遵守该法的其他所有规定（然而，请参阅附注）。
| CUSIP编号 No. 10919W405 | 13G | 第2页 共 第11页 |
1. |
报告人姓名
PFM健康科学有限合伙 |
2. |
若为集团成员，请勾选正确的方格 (a) ¨ (b) x |
3. |
本局使用
|
4.
|
公民身份或组织地点 特拉华州 |
持有人数 股份 被实益拥有 所有权 每个股票持有人 报告有关人士持有之股份 个人 带著
|
5. |
共同拥有表决权的股份数量 0 |
6. |
每位申报人持有之受益股份数量 0股份
| |
7. |
唯一的处分权力 0 | |
8.
|
共同处分权力 See Row 6 above |
9. |
每家报告人拥有的受益股份总额 See Row 6 above | |
10. |
核取方块 如果第(9)行的总金额不包括某些股份 |
¨ |
11. |
所代表类别的百分比在第9行中
0.0%1 | |
12.
|
报告人类别 IA; PN | |
| 1 | 本13G表所报告的百分比是基于4463837股普通股（根据发行人于2023年12月29日向证券交易委员会提交的20-F表格）。 |
| CUSIP编号 No. 10919W405 | 13G | 第3页 的 第11页 |
1. |
报告人姓名
PFm健康科学GP，有限责任公司 |
2. |
若为集团成员，请勾选正确的方格 (a) ¨ (b) x |
3. |
本局使用
|
4.
|
公民身份或组织地点 特拉华州 |
持有人数 股份 被实益拥有 所有权 每个股票持有人 报告有关人士持有之股份 个人 带著
|
5. |
共同拥有表决权的股份数量 0 |
6. |
每位申报人持有之受益股份数量 0股份
| |
7. |
唯一的处分权力 0 | |
8.
|
共同处分权力 See Row 6 above |
9. |
每家报告人拥有的受益股份总额 See Row 6 above | |
10. |
核取方块 如果第(9)行的总金额不包括某些股份 |
¨ |
11. |
所代表类别的百分比在第9行中
0.0% | |
12.
|
报告人类别 OO | |
| CUSIP编号 No. 10919W405 | 13G | 第 4 页 第11页 |
1. |
报告人姓名
合作伙伴资产管理，LLC |
2. |
若为集团成员，请勾选正确的方格 (a) ¨ (b) x |
3. |
本局使用
|
4.
|
公民身份或组织地点 特拉华州 |
持有人数 股份 被实益拥有 所有权 每个股票持有人 报告有关人士持有之股份 个人 带著
|
5. |
共同拥有表决权的股份数量 0 |
6. |
每位申报人持有之受益股份数量 0股份
| |
7. |
唯一的处分权力 0 | |
8.
|
共同处分权力 See Row 6 above |
9. |
每家报告人拥有的受益股份总额 See Row 6 above | |
10. |
核取方块 如果第(9)行的总金额不包括某些股份 |
¨ |
11. |
所代表类别的百分比在第9行中
0.0% | |
12.
|
报告人类别 OO | |
| CUSIP编号 No. 10919W405 | 13G | 第 5 页 第11页 |
1. |
报告人姓名
布莱恩·D·格罗斯曼 |
2. |
若为集团成员，请勾选正确的方格 (a) ¨ (b) x |
3. |
本局使用
|
4.
|
公民身份或组织地点 美国公民 |
持有人数 股份 被实益拥有 所有权 每个股票持有人 报告有关人士持有之股份 个人 带著
|
5. |
共同拥有表决权的股份数量 0 |
6. |
每位申报人持有之受益股份数量 0股份
| |
7. |
唯一的处分权力 0 | |
8.
|
共同处分权力 See Row 6 above |
9. |
每家报告人拥有的受益股份总额 See Row 6 above | |
10. |
核取方块 如果第(9)行的总金额不包括某些股份 |
¨ |
11. |
所代表类别的百分比在第9行中
0.0% | |
12.
|
报告人类别 IN | |
| CUSIP编号 No. 10919W405 | 13G | 页面 6 的 第11页 |
| 项目1(a) | 发行人 名称 |
明心生物科学 公司。
| 项目 1(b) | 发行人主要行政办公室地址 |
| 19 Vestry Street, New York, NY 10013 |
| 项目 2(a) | 申报人姓名 此13G表格由PFm Health Sciences, LP（“PFM”）、PFm Health Sciences GP, LLC（“PFm-GP”）、Partner Asset Management, LLC（“PAM”） 和Brian D. Grossman（“Grossman”和PFm、PFm-GP和PAm合称为“报告人”）共同递交，涉及由PFm Healthcare Master Fund, L.P.（一家开曼群岛有限合伙公司“HCM”）拥有的上述发行人的普通股。 |
PFM is the investment advisor for HCM. PAM is the general partner of HCM. PFM-GP is the general partner of PFM and the manager of PAM. Grossman is the sole member of PFM-GP.
The filing of this statement shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any securities covered by the statement other than the securities actually owned by such person (if any).
| Item 2(b) | Address
or Principal Business Office or, if none, Residence The address of the principal business office of each of the Reporting Persons is c/o PFM Health Sciences, LP, 475 Sansome Street, Suite 1720, San Francisco, California 94111. |
| Item 2(c) | Citizenship PFM is organized as a limited partnership under the laws of the State of Delaware. Each of PFM-GP, HCG-GP and PAM is organized as a limited liability company under the laws of the State of Delaware. Grossman is a U.S. citizen. |
| Item 2(d) | Title
of Class of Securities Common Shares, Without Par Value |
| Item 2(e) | CUSIP Number 10919W405 |
| CUSIP No. 10919W405 | 13G | Page 7 of 11 Pages |
| Item 3 | If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a: |
| (a) | ¨ | Broker or dealer registered under Section 15 of the Exchange Act; |
| (b) | ¨ | Bank as defined in Section 3(a)(6) of the Exchange Act; |
| (c) | ¨ | Insurance company as defined in Section 3(a)(19) of the Exchange Act; |
| (d) | ¨ | Investment company registered under Section 8 of the Investment Company Act; |
| (e) | ¨ | An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E); |
| (f) | ¨ | An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F); |
| (g) | ¨ | A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G); |
| (h) | ¨ | A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act; |
| (i) | ¨ | A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act; |
| (j) | ¨ | A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J); | |
| (k) | ¨ | Group, in accordance with Rule 13d-1(b)(1)(ii)(K). | |
If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution: ____________.
| CUSIP No. 10919W405 | 13G | Page 8 of 11 Pages |
| Item 4 | Ownership |
| A. | PFM Health Sciences, LP, PFM Health Sciences GP, LLC, and Partner Asset Management, LLC |
| (a) | PFM, PFM-GP and PAM may be deemed to beneficially own 0 shares of Common Shares. |
| (b) | The number of shares PFM, PFM-GP and PAM may be deemed to beneficially own constitutes approximately 0.0% of the Common Shares outstanding. |
| (c) | Number of shares as to which such person has: |
| (i) | sole power to vote or to direct the vote: 0 |
| (ii) | shared power to vote or to direct the vote: 0 |
| (iii) | sole power to dispose or to direct the disposition of: 0 |
| (iv) | shared power to dispose or to direct the disposition of: 0 |
| B. | Brian D. Grossman |
| (a) | Grossman may be deemed to beneficially own 0 shares of Common Shares. |
| (b) | The number of shares Grossman may be deemed to beneficially own constitutes approximately 0.0% of the Common Shares outstanding. |
| (c) | Number of shares as to which such person has: |
| (i) | sole power to vote or to direct the vote: 0 |
| (ii) | shared power to vote or to direct the vote: 0 |
| (iii) | sole power to dispose or to direct the disposition of: 0 |
| (iv) | shared power to dispose or to direct the disposition of: 0 |
| Item 5 | Ownership of Five Percent
or Less of a Class If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following x. |
| Item 6 | Ownership of More than Five Percent on Behalf of Another Person |
Not Applicable
| Item 7 | Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company |
See Item 2 above
| CUSIP No. 10919W405 | 13G | Page 9 of 11 Pages |
| Item 8 | Identification and Classification of Members of the Group |
Not Applicable
| Item 9 | Notice of Dissolution of Group |
Not Applicable
| Item 10 | Certification By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. |
| CUSIP No. 10919W405 | 13G | Page 10 of 11 Pages |
After reasonable inquiry and to the best of its knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.
Dated this 22nd day of October, 2024.
| PFM Health Sciences, LP | PFM Health Sciences GP, LLC | |||
| By: | PFM Health Sciences GP, LLC, | By: | /s/ Darren Mooney | |
| its general partner | Darren Mooney, Authorized Signatory | |||
| By: | /s/ Darren Mooney | |||
| Darren Mooney, Authorized Signatory | ||||
| PARTNER Asset MANAGEMENT, LLC | BRIAN D. GROSSMAN | |||
| By: | PFM Health Sciences GP, LLC, | By: | /s/ Darren Mooney | |
| its manager | Darren Mooney, attorney-in-fact* | |||
| By: | /s/ Darren Mooney | |||
| Darren Mooney, Authorized Signatory | ||||
| * | Darren Mooney is signing on behalf of Brian Grossman as attorney-in-fact pursuant to a power of attorney dated February 1, 2024, and incorporated by reference herein. The power of attorney was filed as an attachment to a filing by certain of the Reporting Persons on Schedule 13G/A for Praxis Precision Medicines, Inc. on February 14, 2024. |